BIVI Stock Overview
A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.36 |
| 52 Week High | US$33.10 |
| 52 Week Low | US$1.04 |
| Beta | 1.04 |
| 1 Month Change | -14.49% |
| 3 Month Change | 101.71% |
| 1 Year Change | -81.27% |
| 3 Year Change | -94.86% |
| 5 Year Change | -92.13% |
| Change since IPO | -99.37% |
Recent News & Updates
Shareholder Returns
| BIVI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.0% | 1.2% | 0.7% |
| 1Y | -81.3% | -7.0% | 23.0% |
Return vs Industry: BIVI underperformed the US Biotechs industry which returned -6.6% over the past year.
Return vs Market: BIVI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| BIVI volatility | |
|---|---|
| BIVI Average Weekly Movement | 35.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIVI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIVI's weekly volatility has increased from 25% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 14 | Cuong Viet Do | bioviepharma.com |
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program.
BioVie Inc. Fundamentals Summary
| BIVI fundamental statistics | |
|---|---|
| Market cap | US$43.82m |
| Earnings (TTM) | -US$26.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs BIVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIVI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$26.77m |
| Earnings | -US$26.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 23.6% |
How did BIVI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 02:25 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioVie Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Jay Olson | Oppenheimer & Co. Inc. |